NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN)

Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 20, 2

The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While

BALA CYNWYD, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi

Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Ther

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300

Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's r

Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal

Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.

U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout,

U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence T

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence”)

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technolog

The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically

Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which

Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are

Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference T

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence

The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in S

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Compan

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight

Silence Therapeutics (NASDAQ: SLN) reported top-line results from its Phase II SANRECO trial of dive

Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesi

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran i

Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul

Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera.

BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained

Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the anal

Avalon Holdings (NYSE:AWX) shares rose 10.5% in pre-market trading after posting strong Q2 earnings

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics (NASDAQ:SLN)

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and qu

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the anal

Urgent.ly shares surged in pre-market trading after agreement to be acquired by Agero for $5.50 per